Valeant Pharmaceuticals Intl Inc. Has Lost $100 Billion in Value Since August. Is it Going to $0?

With nearly no clarity into the company’s startling allegations, it’s tough to recommend that anyone should own Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

The Motley Fool

It’s not often that you see companies worth $150 billion lose two-thirds of their market cap in a matter of months. Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), however, is one of those rare cases.

The company is billed as a “specialty pharmaceutical roll-up.” Essentially, it has historically been very aggressive with acquisitions, buying up companies and slashing the research and development budgets. Once the costs are gutted, they mark up the cost of their drugs significantly. Since 2010, this strategy has proven quite successful. Over the past five years, revenues are up over 1,000%, with profits jumping to roughly $1 billion.

What has caused it to lose over 60% of its value in the past 90 days?

Attacks from short sellers

Funds that engage in short selling profit when stocks decline. Citron Research is widely respected as one of the best, with its research being widely read on Wall Street. That’s why when the company targeted Valeant, people listened.

Citron’s primary claim is that Valeant uses a network of specialty pharmacies that the company controls to create false demand for its products, propping up sales for its high-priced drugs and keeping patients and their insurance companies from switching to less costly generic drugs. If this is true, it could have extreme ramifications for the entire business. Recently, Citron Research updated its price target to $0.

Pressure is mounting

The bad news seems to be growing for Valeant. This week Valeant disclosed that it had received a subpoena from the U.S. Department of Justice regarding its Bausch & Lomb division. It is also facing numerous lawsuits from investors, former business partners, and government agencies such as the FBI. Lately, the company has also been receiving some difficult press from some well-known names.

Last week, Berkshire Hathaway Inc. CEO Charlie Munger issued a statement calling Valeant’s practice of acquiring drugs and then jacking the prices “deeply immoral.” Munger also questioned Valeant’s quality of earnings, saying that its accounting practices were less than reliable. Meanwhile, Goldman Sachs Group Inc. announced that it was downgrading Valeant, stating that they “have less confidence the market will reward the stock anytime soon.”

Buy or sell?

Investigations typically can take a long time. Regaining investor trust can take even longer. Even if the allegations turn out to be false, Valeant may never fully recover. The only voice of support seems to be from one of its largest shareholders, Bill Ackman, the CEO of Pershing Square. There may be some bias, however, as his losses on the stock are estimated to be around $2 billion.

With nearly no clarity on the company’s allegations, it’s tough to recommend to anyone that they should hold the stock. You’re most likely better off owning a business that you know well and have more information about.

Fool contributor Ryan Vanzo has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Berkshire Hathaway and Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »